The role of wide-spectrum cytokeratin staining of the bone marrow cores in patients with ductal carcinoma of the breast.

Abstract

The usefulness of routine pancytokeratin staining of bone marrow cores (BMCs)--negative for hematoxylin and eosin (HE)--from patients with lobular carcinoma of the breast has been fairly well established. However, the role of wide-spectrum cytokeratin staining of HE-negative BMCs from patients with ductal carcinoma has not been as well determined and is the purpose of this study. Forty-two prospectively and retrospectively reviewed He-negative BMCs from 21 patients with ductal breast carcinoma failed to reveal staining with a wide-spectrum cytokeratin stain, supporting the selective use of this immunostain in "suspicious" cases with atypical cells detected in HE BMCs.

• Authors: C H Dunphy
• Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (Mod Pathol) Vol. 9 Issue 10 Pg. 955-8 (Oct 1996) ISSN: 0893-3952 [Print] United States
• PMID: 9005447 (Publication Type: Journal Article)

Chemical References

• Biomarkers, Tumor
• Keratins

Topics

• Biomarkers, Tumor (analysis)
• Bone Marrow (chemistry, pathology)
• Bone Marrow Neoplasms (chemistry, secondary)
• Breast Neoplasms (chemistry, pathology)
• Carcinoma, Ductal, Breast (chemistry, secondary)
• Female
• Humans
• Immunoenzyme Techniques
• Keratins (analysis)
• Prospective Studies
• Retrospective Studies
• Staining and Labeling